PBH:NYSEPrestige Consumer Healthcare Inc. Analysis
Data as of 2026-08-24 - not real-time
$51.31
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
The moving-average structure behind Prestige Consumer Healthcare Inc. is neutral at $51.31, with no clear ordering between short and long averages. The last 30 days have gained 4.9%. RSI sits at 51.0, which reads as neutral, and MACD momentum is bearish. Watch $49.03 as support and $55.99 as the nearer resistance level.
Valuation screens as undervalued: a P/E of 14.4 sits below the sector average of 31.1. Consensus targets land 32.1% above where the shares trade now. Revenue is growing at 6.5% on a 15.6% profit margin.
Risk comes out at 6 of a possible 10, a elevated reading. With 30-day volatility of 35.5%, a beta of -0.02 and a maximum drawdown of 35.3%, position sizing matters here. The wider market backdrop reads extreme greed at 94 on the fear-greed composite.
Near-term and long-term part ways here — hold short-term against buy longer out, with 5/10 conviction on the long call.
Valuation screens as undervalued: a P/E of 14.4 sits below the sector average of 31.1. Consensus targets land 32.1% above where the shares trade now. Revenue is growing at 6.5% on a 15.6% profit margin.
Risk comes out at 6 of a possible 10, a elevated reading. With 30-day volatility of 35.5%, a beta of -0.02 and a maximum drawdown of 35.3%, position sizing matters here. The wider market backdrop reads extreme greed at 94 on the fear-greed composite.
Near-term and long-term part ways here — hold short-term against buy longer out, with 5/10 conviction on the long call.
Top Market Events
Updated May 22, 2026 0 Prestige Consumer Healthcare shares fell sharply after Q4 earnings missed consensus estimates --...In early August 2026, Prestige Consumer Healthcare reported fiscal 2027 first‑quarter revenue of US$265.TARRYTOWN, N.Y., July 06, 2026 GLOBE NEWSWIRE -- Prestige Consumer Healthcare Inc. NYSE:PBH 'Prestige” today...
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 1/10
Key Factors
- Trading below the 200-day average of 57.20
- MACD momentum is negative
- Maximum drawdown of 35.3%
Medium Term
1–3 yearsNeutral
Model confidence: 3/10
Key Factors
- P/E of 14.4 versus sector average of 31.1
- Trading below the 200-day average of 57.20
- Analyst targets imply +32.1% versus the current price
Long Term
> 3 yearsPositive
Model confidence: 5/10
Key Factors
- P/E of 14.4 versus sector average of 31.1
- Analyst targets imply +32.1% versus the current price
- Profit margin of 15.6% is healthy
Key Metrics & Analysis
Financial Health
Revenue Growth6.50%
Profit Margin15.57%
P/E Ratio14.4
ROE9.12%
ROA4.58%
Debt/Equity107.86
P/B Ratio1.3
Op. Cash Flow$249.4M
Free Cash Flow$147.9M
Industry P/E31.1
Technical Analysis
TrendNeutral
RSI51.0
Support$49.03
Resistance$55.99
MA 20$51.82
MA 50$49.68
MA 200$57.20
MACDBearish
VolumeDecreasing
Fear & Greed Index94.41
Valuation
Fair Value$10.94
Target Price$67.80
Upside/Downside32.14%
GradeUndervalued
TypeBlend
Risk Assessment
Beta-0.02
Volatility35.48%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.